BioSpace News Archive

In response to the COVID-19 pandemic, ZOOM+Care, a leading provider of retail and virtual healthcare, began offering drive-thru testing on Thursday, April 9th.

Lydia McClure, Ph.D., a University of Texas at Austin-educated virologist who serves as Research Bridge Partners’ Vice President of Scientific Partnerships, is an expert on the roles of federal funding and academic research in developing scientific breakthroughs that address critical public needs.

Centene (NYSE: CNC) today announced a series of investments to address the social determinants of health for vulnerable populations during the COVID-19 crisis. These actions build on the company’s long-standing commitment to research and investment in areas related to the social determinants of health, which are the non-medical barriers to achieving quality health outcomes.

Versant Health, a leading national managed eye health and vision plan company, is proud to welcome Kristyn Parzynski, as its new Vice President, Labor Sales.

AliveCor, the leader in AI-based, personal ECG technology, today announced it will offer a QTc measurement service on ECGs from AliveCor’s KardiaMobile 6L, the world’s only FDA-cleared six-lead personal ECG.

180,000 new claims processed for telephone and virtual visits in March, along with 50,000 new claims for COVID-19 testing and care

Clearsight Advisors, Inc. (“Clearsight”) is pleased to announce another successful transaction in its market-leading Healthcare / Life Sciences Consulting and Outsourcing Practice.

Many processes that generate electricity also produce heat, a potent energy resource that often goes untapped everywhere from factories to vehicles to power plants. An innovative system currently being developed at the U.S. Department of Energy’s (DOE) Argonne National Laboratory can quickly store heat and release it for use when needed, surpassing conventional storage options in both flexibility and efficiency

Ridgeback Biotherapeutics LP, a closely held biotechnology company, announced clearance by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for an orally available antiviral compound, EIDD-2801, to begin human testing. This ac

Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, today announces top-line revenue guidance for the quarter ended March 31, 2020. Alimera expects to report consolidated net revenue for the first quarter of 2020 exceeding $14 million, which compares to $12.9 million in the first qu